Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METADOXINE FOR USE AS INHIBITOR OF HEPATIC FIBROSIS
Document Type and Number:
WIPO Patent Application WO/2010/100619
Kind Code:
A1
Abstract:
The use of metadoxine in the treatment of hepatic fibrosis is described. Metadoxine can be orally and/or parenterally administered at a dosage comprised between 50 and 1000 mg per dose, preferably between 300 and 600 mg per dose. In the in vitro study, metadoxine results effective at lower concentrations with respect to those that are obtained in the plasma after oral administration at the doses recommended for conventional pathology.

Inventors:
BALDACCI, Massimo (Lungarno Gambacorti 42, Pisa, I-56125, IT)
Application Number:
IB2010/050930
Publication Date:
September 10, 2010
Filing Date:
March 04, 2010
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
LABORATORI BALDACCI SPA (Via San Michele degli Scalzi 73, Pisa, I-56100, IT)
BALDACCI, Massimo (Lungarno Gambacorti 42, Pisa, I-56125, IT)
International Classes:
A61K31/4015; A61K31/4415; A61P1/16
Other References:
MURIEL PABLO ET AL: "Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine." LIVER INTERNATIONAL, vol. 23, no. 4, August 2003 (2003-08), pages 262-268, XP002552816 ISSN: 1478-3223
ANNONI G ET AL: "PYRIDOXOL L 2-PYRROLIDON-5 CARBOXYLATE PREVENTS ACTIVE FIBROPLASIA IN CARBON TETRACHLORIDE TREATED RATS" PHARMACOLOGICAL RESEARCH, vol. 25, no. 1, 1992, pages 87-94, XP008114043 ISSN: 1043-6618
AROSIO B ET AL: "Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl-4-induced liver fibrosis: Effect of pyridoxol L,2-pyrrolidon-5 carboxylate" PHARMACOLOGY AND TOXICOLOGY, vol. 73, no. 6, 1993, pages 301-304, XP002552817 ISSN: 0901-9928
MURIEL P ET AL: "Metadoxine partially prevents fibrosis and completely preserves glycogen stores in prolonged biliary obstruction in the rat: A comparison with colchicine." JOURNAL OF HEPATOLOGY, vol. 38, no. Supplement 2, April 2003 (2003-04), page 79, XP002552818 & 38TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; INSTANBUL, TURKEY; MARCH 29-APRIL 01, 2003 ISSN: 0168-8278
MEDINA J ET AL: "Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis" DIABETES CARE 200408 US, vol. 27, no. 8, August 2004 (2004-08), pages 2057-2066, XP002584426 ISSN: 0149-5992
CACCIATORE L ET AL: "METADOXINE TREATMENT OF FATTY LIVER ASSOCIATED WITH CHRONIC HEPATITIS" CLINICAL TRIALS JOURNAL, vol. 25, no. 3, 1988, pages 220-226, XP008114048 ISSN: 0009-9325
ADDOLORATO G; ANCONA C; CAPISTO E; GASBARRINI G METADOXINE IN THE TREATMENT OF ACUTE AND CHRONIC ALCOHOLISM
DIAZ MARTINEZ MCLR; DIAZ MARTINEZ A; VILLAMIL SALCEDO V; CRUZ FUENTES C: 'Efficacy in the management of acute alcohol intoxication' J INT MED RES vol. 30, 2002, pages 44 - 51
SANTONI S; CORRADINI P; ZOCCHI M; CAMARRI F: 'La metadoxina nella patologia alcol-correlata' LA CLINICA TERAPEUTICA vol. 130, 1989, pages 115 - 122
CALABRESE V; CARLINO S; CHINNICI V; DE BERNARDIS E; RIZZA V: 'La metadoxina modula le cinetiche di assorbimento, metabolismo ed eliminazione dell'etanolo' ALCOLOGIA vol. 5, 1986, pages 1 - 2
INTASCHI G; LATTANZI L; LOMBARDI G; PANZERA V; GUAZZELLI M; MAGGINI C: 'Gli effetti della metadoxina nella dipendenza da alcol: implicazioni per lo studio dei rapporti tra alcolismo e depressione' PROGRESSI IN PSICHIATRIA - ESTRATTI DAL CONGRESSO 06 February 1989,
CARBONI MA; CORSI R: 'Uso terapeutico della metadoxina nei disturbi psichici e comportamentali alcol-correlati' CLIN TER vol. 123, 1987, pages 469 - 473
WALLACE K; BURT AD; WRIGHT MC: 'Liver fibrosis' BIOCHEM J vol. 411, 2008, pages 1 - 18
PINZONI M; ROMBOUTS K: 'Liver Fibrosis: from the bench to clinical targets' DIGESTIVE AND LIVER DISEASE vol. 36, 2004, pages 231 - 242
BATALLER, R; BREMER DA: 'Liver fibrosis' J CLIN INV vol. 115, 2005, pages 209 - 218
See also references of EP 2403495A1
Attorney, Agent or Firm:
PISTOLESI, Roberto et al. (Via Marina 6, Milan, I-20121, IT)
Download PDF:
Claims:
CLAIMS

1) Metadoxine for use in the treatment of hepatic fibrosis, characterized in that said metadoxine is orally administered to a human.

2) Metadoxine according to claim 1, characterized in that said hepatic fibrosis is non-alcohol dependent fibrosis (NASH).

3) Metadoxine according to claim 1, characterized in that said hepatic fibrosis is generated by an acute or chronic inflammatory state of the liver.

4) Metadoxine according to claim 1, characterized in that said hepatic fibrosis is associated with the presence of hepatic viruses, hyperlipidemia, hyperglycemia and/or other altered metabolic factors.

5) Metadoxine according to claim 1, characterized in that said formulation has a metadoxine content comprised between 50 and 1000 mg per dose.

6) Metadoxine according to claim 5, characterized in that said formulation has a metadoxine content comprised between 300 and 600 mg per dose.

7) Metadoxine according to claims 1 to 6, characterized in that said dose is administered 2 or 3 times per day.

8) Metadoxine according to claims 1 to 7, characterized in that said formulation is in tablet, capsule or solution form.

Description:
Title

Metadoxine for use as inhibitor of hepatic fibrosis.

The object of the present invention is represented by the therapeutic use of metadoxine in the treatment of hepatic fibrosis.

Background art

Metadoxine, or Pyridoxol L-2-pyrrolidone-5-carboxylate, whose structure formula is reported hereinbelow

is known for its effectiveness in acute and chronic alcoholism and for the prevention of alcohol related pathology (1, 2, 3); metadoxine is currently sold as active ingredient of the Metadoxil drug. The ability of metadoxine to accelerate the elimination of alcohol from plasma and from tissues (4), to reduce the damages alcohol-induced on the structure and functionality level of the hepatocyte is well documented, together with its effectiveness against neuropsychological disorders present in chronic alcoholics (5, 6).

Nevertheless, up to date it has never been shown that such substance can intervene on the biomechanical mechanisms that give origin to fibrosis, which represents the key pathogenetic outcome of all the hepatic diseases evolving towards the cirrhosis of any etiology (7).

The most recent data reported in the literature recognizes fibrogenesis as the common mechanism of hepatic pathology developing due to inflammation, associated with the presence of hepatic viruses, immunological processes or predisposing factors such as diabetes, obesity, hyperlipidemia and an incorrect diet (8, 9).

Hepatic fibrosis is an excessive accumulation of extracellular protein matrix in the presence of any one chronic inflammatory disease. The progression of hepatic fibrosis is very slow and the plasmatic parameters that are normally carried out for evaluating hepatic functionality are not universally accepted as indicators of fibrosis severity and vary slightly with the progression of the disease. Various non-invasive methods have been proposed that are useful for predicting the degree of hepatic fibrosis, but only the hepatic biopsy with the histological exam is considered the "gold standard" parameter that identifies the severity and the progression of the fibrosis.

The study of the genesis and evolution of hepatic fibrosis from a clinical standpoint is difficult to approach and consequently the treatment is usually aimed to eliminate the causes of chronic inflammation due to viral infection, autoimmune phenomena or metabolic alterations. Removing the causes of the inflammatory process (e.g. elimination of the virus) can slow the fibrogenesis or even bring the structural modifications that originated in the liver back to normality. However, in some cases, the fibrosis can develop into cirrhosis and lead to severe clinical complications which require liver transplant even when the causes of chronic inflammation are eliminated.

There is no standard treatment for hepatic fibrosis. The ideal antifibrotic treatment consists of a substance which should be liver-specific, well tolerated even when administered over long time periods and effective in reducing the excessive deposition of collagen without leading to modifications of the normal metabolism of the hepatic stellate cells.

Among the drugs which are proposed as antifibrotic agents, there are the corticosteroids, due to their anti-inflammatory activity, the antioxidants (vitamin E, S-adenosylmethionine), the phosphodiesterase inhibitors (pentoxyphylline) and the inhibitors of the renin-angiotensin system.

It is universally known that fibroblasts are the greatest producers of collagen in the liver that is subjected to chronic inflammatory episodes. The model of human fibroblasts in vitro therefore represents the most standardized method for showing the proliferation of these cells and for the analysis of the mediators involved in cellular development. For this reason, we have conducted an in vitro study, which is detailed in the Experimental Part of this document, in order to show the inhibitory effect of metadoxine on hepatic fibrogenesis.

The experimental results obtained and described in the Experimental Part of this document show the antifibrotic activity of metadoxine, which could therefore be used in all the hepatic pathology forms in which the hepatic damage is due to a fibrotic process with the evolution of the disease towards more severe pathologies such as cirrhosis or hepatic carcinoma. Experimental section

The methods used allow evaluating the effect of substances provided with potential antifibrotic activity on the proliferation of fibroblasts. A line of immortalized human fibroblasts was used, maintained in a culture in a suitable medium.

In order to carry out the proliferation experiments, the fibroblasts were detached from the flask by means of trypsinization, counted and distributed on 96-well flat- bottom plates at the concentration of 2000 cells/1 OOμl medium. Scalar concentrations of metadoxine were added (range of concentration from 10 " 11 M tO lO- 3 M).

The plates were maintained in CO 2 incubator at 37°C. The proliferation of the cells was measured at 24 h intervals up to 12Oh by using the Mosmann method (10), based on the spectrophotometer determination of the conversion of MTT [3- (4,5 dimethylthiazole-2-yl)-2-5 diphenyltetrazolium bromide] to its blue reduction product, formazan, by mitochondrial enzymes of the metabolically active cells. The optical densities (O.D.) were determined by means of the Titertek Multiscan (Flow) spectrophotometer with 540nm filter.

The O.D. s of the samples are expressed as percentages of the samples with respect to the control group. Metadoxine was added in various concentrations (10 "11 M - 10 '3 M range) and at 10 "5 M concentration the effect of the studied product on the growth of fibroblasts as metabolically active cells, capable of affecting the synthesis of fibrinogen, is clear.

In figure 1, the anti-fibrotic activity of metadoxine is reported, expressed in percent with respect to the control group, measured after 12Oh from the first treatment, with treatments repeated every 24h, according to the standardized technique (9).

As can be shown from the obtained experimental results, metadoxine is capable of inhibiting the fibrogenic activity of fibroblasts already at 10 "5 M concentrations.

Such experimental model is normally used for testing the anti-fibrotic activity of substances which also result effective in human hepatic pathology.

Our data demonstrates that metadoxine possesses an anti-fibrotic activity in a range of concentrations comprised between 10 " M and 10 "5 M. Such activity is comparable to that of corticosteroids and is perhaps even greater. Metadoxine can therefore be employed for such activity as an inhibitor of hepatic fibrogenesis.

Conclusions

The results obtained with this in vitro study (the percentage values reported in the figure represent the average of three experimental tests) are of undoubted scientific interest due to the fact that they show the inhibitory activity of metadoxine on hepatic fibrogenesis. It should be underlined that the concentrations at which the product is effective are 2-3 lower than those that are obtained in vivo in the patient orally treated with 500 mg metadoxine dose, in conventional pathologies.

In addition, the optimal tolerability of the metadoxine product has been well known on the market for many years, and it has been used as a protector drug against alcohol-induced tissue damages; its present use as a molecule that can affect hepatic fibrogenesis acquires further therapeutic significance.

The object of the present invention is therefore represented by metadoxine in the treatment of hepatic fibrosis, preferably non-alcohol dependent (NASH) and, in particular, in pharmaceutical formulations based on metadoxine usable for the treatment of hepatic fibrosis.

Metadoxine results effective in hepatic fibrosis due to an acute and/or chronic inflammatory state of the liver; such pathology can also be associated with the presence of hepatic viruses, with hyperlipidemia, with hyperglycemia and/or with other altered metabolic factors.

Further object of the present invention is therefore represented by metadoxine in the treatment of hepatic fibrosis associated with an acute and/or chronic inflammatory state of the liver and/or with the presence of hepatic viruses, with hyperlipidemia, with hyperglycemia and/or with other altered metabolic factors. In the treatment of hepatic fibrosis, metadoxine and/or the formulations containing it are orally administered, preferably to a human. A further aspect of the invention can be specified in the formulations containing metadoxine which are preferably in tablet, capsule and oral solution form, and have a metadoxine content comprised between 50 and 1000 mg per dose, preferably between 300 and 600 mg per dose.

Furthermore, in the treatment of hepatic fibrosis, the aforesaid dosage comprised between 50 and 1000 mg of metadoxine per dose, preferably between 300 and 600 mg per dose, is preferably administered by means of a dosage 2 or 3 times per day.

Bibliography

1) Addolorato G, Ancona C, Capisto E, Gasbarrini G: Metadoxine in the treatment of acute and chronic alcoholism: a review.

2) Diaz Martinez MCLR, Diaz Martinez A, Villamil Salcedo V, Cruz Fuentes C: Efficacy in the management of acute alcohol intoxication. J hit Med Res, 2002; 30: 44-51.

3) Santoni S, Corradini P, Zocchi M, Camarri F: La metadoxina nella patologia alcol-correlata. La Clinica Terapeutica, 1989; 130: 115-122.

4) Calabrese V, Carlino S, Chinnici V, De Bernardis E, Rizza V: La metadoxina modula Ie cinetiche di assorbimento, metabolismo ed eliminazione dell'etanolo. Alcologia, 1986; 5(1-2).

5) Intaschi G, Lattanzi L, Lombardi G, Panzera V, Guazzelli M, Maggini C: GIi effetti della metadoxina nella dipendenza da alcol: implicazioni per Io studio dei rapporti tra alcolismo e depressione. Progressi in Psichiatria - Estratti dal Congresso - Roma 6-11 febbraio 1989.

6) Carboni MA, Corsi R: Uso terapeutico della metadoxina nei disturbi psichici e comportamentali alcol-correlati. Clin Ter, 1987; 123: 469-473.

7) Wallace K, Burt AD, Wright MC: Liver fibrosis. Biochem J, 2008; 411:1-18. 8) Pinzoni M, Rombouts K: Liver Fibrosis: from the bench to clinical targets. Digestive and Liver Disease, 2004; 36: 231-242.

9) Bataller, R, Bremer DA: Liver fibrosis. J Clin Inv, 2005; 115: 209-218.